bifeprunox has been researched along with piperidines in 2 studies
Studies (bifeprunox) | Trials (bifeprunox) | Recent Studies (post-2010) (bifeprunox) | Studies (piperidines) | Trials (piperidines) | Recent Studies (post-2010) (piperidines) |
---|---|---|---|---|---|
30 | 1 | 12 | 40,235 | 5,221 | 14,545 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Corsini, GU; Maggio, R; Millan, MJ; Novi, F | 1 |
Arnt, J; Bétry, C; Etievant, A; Haddjeri, N | 1 |
2 other study(ies) available for bifeprunox and piperidines
Article | Year |
---|---|
Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzoxazoles; Carrier Proteins; Chlorocebus aethiops; Clozapine; COS Cells; Cricetinae; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Piperazines; Piperidines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Transfection | 2007 |
Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Topics: Action Potentials; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Indoles; Male; Neurons; Piperazines; Piperidines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Sulfones; Tetrahydronaphthalenes; Ventral Tegmental Area | 2009 |